These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17023870)

  • 21. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder.
    Zeni CP; Guimarães AP; Polanczyk GV; Genro JP; Roman T; Hutz MH; Rohde LA
    Am J Med Genet B Neuropsychiatr Genet; 2007 Apr; 144B(3):391-4. PubMed ID: 17171656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children.
    Cheon KA; Kim BN; Cho SC
    Neuropsychopharmacology; 2007 Jun; 32(6):1377-83. PubMed ID: 17077808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine transporter genotype and methylphenidate dose response in children with ADHD.
    Stein MA; Waldman ID; Sarampote CS; Seymour KE; Robb AS; Conlon C; Kim SJ; Cook EH
    Neuropsychopharmacology; 2005 Jul; 30(7):1374-82. PubMed ID: 15827573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis.
    Stuckelman ZD; Mulqueen JM; Ferracioli-Oda E; Cohen SC; Coughlin CG; Leckman JF; Bloch MH
    J Clin Psychiatry; 2017 Jun; 78(6):e648-e655. PubMed ID: 28682529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.
    Angyal N; Horvath EZ; Tarnok Z; Richman MJ; Bognar E; Lakatos K; Sasvari-Szekely M; Nemoda Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):122-128. PubMed ID: 29374517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.
    Palumbo D; Spencer T; Lynch J; Co-Chien H; Faraone SV
    J Child Adolesc Psychopharmacol; 2004; 14(2):185-94. PubMed ID: 15319016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.
    Leddy JJ; Waxmonsky JG; Salis RJ; Paluch RA; Gnagy EM; Mahaney P; Erbe R; Pelham WE; Epstein LH
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):127-36. PubMed ID: 19364291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.
    Bellgrove MA; Hawi Z; Kirley A; Fitzgerald M; Gill M; Robertson IH
    Neuropsychopharmacology; 2005 Dec; 30(12):2290-7. PubMed ID: 16123773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
    Chronis-Tuscano A; Seymour KE; Stein MA; Jones HA; Jiles CD; Rooney ME; Conlon CJ; Efron LA; Wagner SA; Pian J; Robb AS
    J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder.
    Park SY; Kim EJ; Cheon KA
    J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):633-40. PubMed ID: 26402385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of methylphenidate in patients with cerebral palsy and attention-deficit hyperactivity disorder (ADHD).
    Gross-Tsur V; Shalev RS; Badihi N; Manor O
    J Child Neurol; 2002 Dec; 17(12):863-6. PubMed ID: 12593456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Interaction Between DRD4 Methylation and Prenatal Maternal Stress on Methylphenidate-Induced Changes in Continuous Performance Test Performance in Youth with Attention-Deficit/Hyperactivity Disorder.
    Kim JI; Kim JW; Shin I; Kim BN
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):562-570. PubMed ID: 29905488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.
    Kim BN; Kim JW; Cummins TD; Bellgrove MA; Hawi Z; Hong SB; Yang YH; Kim HJ; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
    J Clin Psychopharmacol; 2013 Jun; 33(3):356-62. PubMed ID: 23609393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
    Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A
    Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder.
    Bouffard R; Hechtman L; Minde K; Iaboni-Kassab F
    Can J Psychiatry; 2003 Sep; 48(8):546-54. PubMed ID: 14574830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.